<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023464</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-030</org_study_id>
    <nct_id>NCT01023464</nct_id>
  </id_info>
  <brief_title>Tear Film Break-Up Time Evaluation of FID 114657</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of FID 114657 on tear film break-up time in dry eye patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tear film break-up time (TFBUT)</measure>
    <time_frame>Instill assigned test article to both eyes and begin timing the evaluation process. Measure TFBUT at 15, 30, 60 and 120 minutes post instillation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute comfort</measure>
    <time_frame>Immediately post instillation of test article</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FID 114657 or SootheXP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FID 114657 or SootheXP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID114657</intervention_name>
    <description>artificial tears</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SootheXP Emollient (Lubricant) Eye Drops</intervention_name>
    <description>artificial tears</description>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The informed consent document and HIPAA privacy document must be read, signed and&#xD;
             dated by the patient or legally authorized representative before conducting any&#xD;
             procedures.&#xD;
&#xD;
          2. Patients (minimum age 18) with dry eye. Criteria for the diagnosis must include the&#xD;
             following characteristics at Visit 1 (Screening): Patients' self-assessment of dry eye&#xD;
             status (answer of at least Some of the time to the question, &quot;How often have your eyes&#xD;
             felt dry enough to want to use eye drops?&quot;);TFBUT &lt;5 seconds in at least one eye; &gt;&#xD;
             Grade 1 for Meibomian Gland Expression in both eyes; Evidence of missing meibomian&#xD;
             glands in both eyes.&#xD;
&#xD;
          3. Able and willing to follow study instructions.&#xD;
&#xD;
          4. Patients must have best-corrected visual acuity of 0.6 logMAR or better in each eye as&#xD;
             assessed using an ETDRS chart at Visit 1.&#xD;
&#xD;
          5. Patients must not have used any topical ocular drops for approximately 24 hours prior&#xD;
             to Visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or evidence of ocular or intraocular surgery in either eye within the past six&#xD;
             months.&#xD;
&#xD;
          2. History or evidence of serious ocular trauma in either eye within the past six months.&#xD;
&#xD;
          3. Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs).&#xD;
&#xD;
          4. History of intolerance or hypersensitivity to any component of the study medications.&#xD;
&#xD;
          5. History or evidence of epithelial herpes simplex keratitis (dendritic keratitis);&#xD;
             vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva;&#xD;
             chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids;&#xD;
             mycobacterial infection of the eye; and/or fungal disease of the eye.&#xD;
&#xD;
          6. Use of any concomitant topical ocular medications during the study period.&#xD;
&#xD;
          7. Patients using systemic medications that may contribute to dry eye (e.g. cold and&#xD;
             allergy medications, tricyclic antidepressants, hormone replacement therapies) may not&#xD;
             be enrolled in the study unless they have been on a stable dosing regimen for a&#xD;
             minimum of 30 days prior to Visit 1. In addition, the dosing regimen must remain&#xD;
             stable throughout the study.&#xD;
&#xD;
          8. Ocular conditions such as conjunctival infections, iritis, or any other ocular&#xD;
             condition that may preclude safe administration of the test article.&#xD;
&#xD;
          9. Individuals unwilling to discontinue contact lens wear during the study period.&#xD;
             Contact lens wear must have been discontinued at least one week prior to Visit 1.&#xD;
&#xD;
         10. Enrollment of investigator's office staff, relatives, or members of their respective&#xD;
             households; or enrollment of more than one member of the same household.&#xD;
&#xD;
         11. Participation in an investigational drug or device study within 30 days of entering&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783-90. doi: 10.2147/OPTH.S13773. Epub 2011 Jun 10.</citation>
    <PMID>21750611</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tear film break-up time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emollients</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

